Abstract
Background and objectives Antimicrobial resistance is a major healthcare burden, aggravated when it extends to multiple drugs. While cross-resistance is well-studied experimentally, it is not the case in clinical settings, and especially not while considering confounding variables. In addition, bacteria from different sample sources may have undergone different evolutionary trajectories, therefore examining cross-resistance across sources is desirable.
Methodology We employed additive Bayesian network (ABN) modelling to examine antibiotic cross-resistance in five major bacterial species, obtained from different sources (urine, wound, blood, and sputum) in a clinical setting, collected in a large hospital in Israel over a 4-year period. ABN modelling allowed for examination of the relationship between resistance to different drugs while controlling for major confounding variables.
Results Patterns of cross-resistance differed across sample sources. All identified links between resistance to different antibiotics were positive, and most were present in several culture sources. However, in 15 of 18 instances, the magnitudes of the links were significantly different between sources compared. For example, E coli exhibited adjusted odds ratios of gentamicin-ofloxacin cross-resistance ranging from 3.0 (95%CI [2.3,4.0]) in urine samples to 11.0 (95%CI [5.2,26.1]) in blood samples.
Conclusions and implications Our results highlight the importance of considering sample sources when assessing likelihood of antibiotic cross-resistance and determining antibiotic treatment regimens and policies.
Abstract Importance We examine the patterns of antibiotic resistance of a given bacterial species, obtained from different clinical infection locations, while accounting for potentially relevant clinical variables. We find that such patterns of cross-resistance between pairs of antibiotics vary between culture sources (e.g., urine vs blood samples), indicating different selective pressures. These findings have implications on prescription policies aiming to minimize collateral resistance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Israel Science Foundation (ISF 1286/21).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board (Helsinki) Committee of Meir Medical Center. Since this was a retrospective study, using archived medical records, an exemption from informed consent was granted by the Helsinki Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are proprietary but can be made available upon reasonable request from the authors.
